The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.
The study objectives are described below: 1. Obtain serum and plasma specimens longitudinally collected from a minimum of 130 subjects diagnosed with breast cancer and are about to or are currently undergoing treatment and follow-up. Specimens will be used to evaluate CA 15-3 assays, currently under development, as an aid for monitoring recurrence or progressive disease. 2. To store any remaining specimens for use in future cancer research and to evaluate as yet undetermined biomarkers for the development of IVDs, including additional CA 15-3 assays, for monitoring the course of disease and therapy in subjects diagnosed with breast cancer.
Study Type
OBSERVATIONAL
Enrollment
130
Physicians use the CA 15-3 test result to manage their patients
Jane Skelton, MD
Boca Raton, Florida, United States
Broward Health Medical Center
Fort Lauderdale, Florida, United States
New Hanover Regional Medical Center
Wilmington, North Carolina, United States
Measure CA 15-3 in Breast Cancer Patients
130 patients with Recurrence or Progressive Breast Cancer.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.